Pfizer: Building The Next Oncology Empire
Summary
$43Bn Seagen acquisition positions Pfizer to dominate the $140Bn antibody-drug conjugate market. Numerous potential bloc...
$43Bn Seagen acquisition positions Pfizer to dominate the $140Bn antibody-drug conjugate market. Numerous potential blockbusters launching pre-2030 should strengthen its oncology portfolio to offse patent cliff impact. Pfizer's 7% yield is well-covered at an 85% FCF payout ratio with a committed dividend growth strategy.
Tags
PFE
Related Articles
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
PFE
PositiveOxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
PFE
PositiveHouse committee subpoenas Pfizer executive in probe of alleged COVID vaccine delay, CNN reports
PFE
Neutral